NASDAQ:GRCL Gracell Biotechnologies (GRCL) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free GRCL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.25▼$10.2550-Day Range$10.14▼$10.3552-Week Range$1.40▼$10.44VolumeN/AAverage Volume1.32 million shsMarket Capitalization$744.95 millionP/E RatioN/ADividend YieldN/APrice Target$13.04 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial Media Get Gracell Biotechnologies alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Gracell Biotechnologies Stock (NASDAQ:GRCL)Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.Read More Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now GRCL Stock News HeadlinesMarch 3, 2024 | finance.yahoo.comGRCL Mar 2024 10.000 call(CONTRFebruary 22, 2024 | finance.yahoo.comGracell Biotechnologies Acquisition CompletedApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 22, 2024 | globenewswire.comGracell Biotechnologies Acquisition CompletedFebruary 21, 2024 | seekingalpha.comAstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)February 21, 2024 | investing.comGracell Biotechnologies Inc. (GRCL)February 20, 2024 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 20, 2024 | finance.yahoo.comGracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 20, 2024 | globenewswire.comGracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 17, 2024 | finance.yahoo.comGRCL Mar 2024 2.500 callFebruary 17, 2024 | seekingalpha.comGRCL Gracell Biotechnologies Inc.January 29, 2024 | finance.yahoo.comGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaJanuary 3, 2024 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?December 31, 2023 | businesswire.comGRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 27, 2023 | markets.businessinsider.comMaintaining Hold on Gracell Biotechnologies Amidst AstraZeneca Acquisition ProspectsDecember 26, 2023 | msn.comWhy China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring TodayDecember 26, 2023 | finance.yahoo.comGracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesDecember 26, 2023 | markets.businessinsider.comGracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market SessionDecember 26, 2023 | tmcnet.comGRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to ShareholdersDecember 21, 2023 | finance.yahoo.comGracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusDecember 21, 2023 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's WhyDecember 12, 2023 | finance.yahoo.comGracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023December 11, 2023 | finance.yahoo.comWall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to TradeDecember 2, 2023 | finance.yahoo.comInstitutions own 19% of Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares but private equity firms control 45% of the companyNovember 29, 2023 | markets.businessinsider.comBuy Rating for Gracell Biotechnologies on Promising CAR-T Cell Therapy AdvancementsNovember 28, 2023 | msn.comEvercore ISI Group Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Outperform RecommendationSee More Headlines Receive GRCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GRCL CUSIPN/A CIK1826492 Webwww.gracellbio.com Phone86-512-6262-6701FaxN/AEmployees314Year FoundedN/APrice Target and Rating Average Stock Price Target$13.04 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+27.2%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.40% Return on Assets-31.24% Debt Debt-to-Equity Ratio0.02 Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual Sales$60,000.00 Price / Sales12,415.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book3.47Miscellaneous Outstanding Shares72,678,000Free Float52,328,000Market Cap$744.95 million OptionableOptionable Beta-0.33 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Wei Cao BM (Age 65)Ph.D., Founder, Chairman & CEO Dr. Yili Xie M.B.A. (Age 53)Ph.D., Chief Financial Officer Dr. Samuel Suhua Zhang M.B.A. (Age 56)Ph.D., Chief Business Officer Dr. Wendy Li M.D. (Age 65)Chief Medical Officer Ms. Erin LiExecutive OfficerKey CompetitorsIcosavaxNASDAQ:ICVXDianthus TherapeuticsNASDAQ:DNTHWave Life SciencesNASDAQ:WVECogent BiosciencesNASDAQ:COGTAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInstitutional OwnershipOctagon Capital Advisors LPBought 596,611 shares on 2/15/2024Ownership: 0.821%TIG Advisors LLCBought 1,279,595 shares on 2/14/2024Ownership: 1.761%Harvest Management LLCBought 400,000 shares on 2/14/2024Ownership: 0.550%Oasis Management Co Ltd.Bought 25,000 shares on 2/14/2024Ownership: 0.034%PenderFund Capital Management Ltd.Bought 22,570 shares on 2/14/2024Ownership: 0.031%View All Institutional Transactions GRCL Stock Analysis - Frequently Asked Questions Should I buy or sell Gracell Biotechnologies stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRCL, but not buy additional shares or sell existing shares. View GRCL analyst ratings or view top-rated stocks. What is Gracell Biotechnologies' stock price target for 2024? 8 brokerages have issued 1-year target prices for Gracell Biotechnologies' stock. Their GRCL share price targets range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $13.04 in the next year. This suggests a possible upside of 27.2% from the stock's current price. View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts. How were Gracell Biotechnologies' earnings last quarter? Gracell Biotechnologies Inc. (NASDAQ:GRCL) released its quarterly earnings data on Sunday, November, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.18. The firm earned $0.06 million during the quarter. When did Gracell Biotechnologies IPO? Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO. This page (NASDAQ:GRCL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gracell Biotechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
